Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging

Trial Profile

Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Kaposi's sarcoma
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 04 Jun 2015 According to Navidea Biopharmaceuticals media release, the data from this trial will be presented at 18th international workshop on Kaposis Sarcoma HerpesVirus (KSHV) and Related Agents in Hollywood, Florida.
    • 03 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Apr 2015 Complete results will be presented in the coming months, as per Navidea Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top